Bromperidol, a new butyrophenone neuroleptic: a review

This review compares and contrasts the preclinical pharmacology of bromperidol with another butyrophenone neuroleptic, haloperidol, and the phenothiazine neuroleptic chlorpromazine. Its pharmacokinetics, biotransformation, and safety in several laboratory animal species are also summarized. These pr...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacology 1982, Vol.78 (1), p.1-7
Main Authors: Dubinsky, B, McGuire, J L, Niemegeers, C J, Janssen, P A, Weintraub, H S, McKenzie, B E
Format: Article
Language:English
Subjects:
Animals
Antipsychotic Agents - pharmacology
Behavior, Animal - drug effects
Binding, Competitive
Biotransformation
Brain - metabolism
Chlorpromazine - metabolism
Chlorpromazine - pharmacology
Dogs
Female
Half-Life
Haloperidol - analogs & derivatives
Haloperidol - metabolism
Haloperidol - pharmacology
Haloperidol - toxicity
Male
Mice
Naloxone - metabolism
Rats
Receptors, Dopamine - drug effects
Receptors, Opioid - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This review compares and contrasts the preclinical pharmacology of bromperidol with another butyrophenone neuroleptic, haloperidol, and the phenothiazine neuroleptic chlorpromazine. Its pharmacokinetics, biotransformation, and safety in several laboratory animal species are also summarized. These preclinical data support its use as an antipsychotic agent and show that it is well absorbed following oral administration with an apparent elimination half-life of approximately 24 h, supporting a once-daily dose regimen. Animal toxicity (including acute- and multiple-dose toxicology and reproductive and mutagenicity studies) show that bromperidol is well tolerated.
ISSN:0033-3158
1432-2072
DOI:10.1007/BF00470578